Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects

Summary Background Immune checkpoint inhibitors have revolutionised the oncological landscape in the last few years. Possible applications include the treatment of hepatocellular carcinoma and cholangiocarcinoma. Unfortunately, new immune‐related adverse effects have been associated with the use of these agents and the liver is one of the organs most frequently involved. Aims To provide a general overview of the potential impact of immune checkpoint inhibitors on the liver Methods We reviewed the literature and abstracts/presentations on immune checkpoint inhibitors at most relevant hepatology meetings over the last 5 years. Results The role of immune checkpoint inhibitors has been investigated both for the treatment of viral hepatitis and primary liver cancer. Hepatocellular carcinoma and chronic hepatitis B show the greatest potential for treatment with these drugs in the near future. However, immune‐related adverse events involving the liver are a growing concern related to their widespread use. Conclusions Immune checkpoint inhibitors represent an exciting new class of drugs with currently limited application in malignant and non‐malignant liver disease. Caution must be exercised on the emergence of potentially severe immune adverse reactions.